FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000061026> ?p ?o ?g. }

• W2000061026 endingPage "800" @default.
• W2000061026 startingPage "794" @default.
• W2000061026 abstract "Background: Despite the increasing recognition of bipolar disorder in childhood, there have been no controlled, randomized clinical trials of atypical antipsychotics in this population. Preliminary data from open-label trials in children suggest that these agents might be effective in treating pediatric bipolar disorder, however. Objective: The purpose of this post hoc analysis of data from Aman et al was to determine the effects of risperidone in the management of affective symptoms in children with disruptive behavioral disorders (DBDs). Methods: This report presents a secondary analysis of a previously reported 6-week, multicenter, double-blind, randomized, parallel-arm trial comparing 6 weeks of administration of risperidone (flexible dosing starting at 0.02 mg · kg ·1 · d−1 and titrated up to 0.06 mg kg−1 d−1) versus placebo in children with DBDs and subaverage intelligence. Twenty-four candidate affective symptoms of mania and depression were extracted from the 64-item Nisonger Child Behavior Rating Form (NCBRF). To define independent dimensions of mood-disorder psychopathology, these 24 symptoms were assigned 1 of 3 independent dimensions (symptoms of mania) based on loading: explosive irritability; agitated, expansive, grandiose; and depression. A fourth, nonaffective independent dimension encompassed a combination of nonaffec tive symptoms on the NCBRF Conduct Problem subscale. To assess treatment effect, each independent dimension was assigned a score derived from the sum of the symptoms that loaded on that dimension at weeks 2, 4, and 6 of study drug administration. Results: A total of 110 patients were included in the independent-dimension analysis (89 boys, 21 girls; risperidone, 49 patients; placebo, 61 patients; mean [SD] age, 8.6 [2.3] and 8.1 [2.4] years in the risperidone and placebo groups, respectively; mean [SD] weight, 33.9 [12.8] and 32.1 [12.0] kg in the risperidone and placebo groups, respectively). The treatment-effect analysis found that the mean scores of all 3 independent dimensions were significantly reduced with risperidone compared with placebo at weeks 2, 4, and 6 (all, P ≤ 0.03). The effect sizes of improvement in these factors ranXged from 0.44 to 0.95 at end point. Conclusions: The results of this post hoc analysis of affective symptoms of DBDs using data from a previously published randomized, double-blind clinical comparison of risperidone and placebo in the treatment of children with DBDs and subaverage intelligence suggest that risperidone was effective in treating the factors of explosive irritability; agitated, expansive, grandiose; and depression." @default.
• W2000061026 created "2016-06-24" @default.
• W2000061026 creator A5024768165 @default.
• W2000061026 creator A5047362217 @default.
• W2000061026 creator A5052145058 @default.
• W2000061026 creator A5069963123 @default.
• W2000061026 creator A5071835676 @default.
• W2000061026 creator A5077744833 @default.
• W2000061026 date "2006-05-01" @default.
• W2000061026 modified "2023-09-27" @default.
• W2000061026 title "Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study" @default.
• W2000061026 cites W1550324952 @default.
• W2000061026 cites W1965614177 @default.
• W2000061026 cites W1987562093 @default.
• W2000061026 cites W1988420031 @default.
• W2000061026 cites W2012788583 @default.
• W2000061026 cites W2015510383 @default.
• W2000061026 cites W2016930196 @default.
• W2000061026 cites W2025218882 @default.
• W2000061026 cites W2033279503 @default.
• W2000061026 cites W2050241324 @default.
• W2000061026 cites W2066174315 @default.
• W2000061026 cites W2116082857 @default.
• W2000061026 cites W2133752375 @default.
• W2000061026 cites W2163181461 @default.
• W2000061026 cites W2167659819 @default.
• W2000061026 doi "https://doi.org/10.1016/s0149-2918(06)00132-9" @default.
• W2000061026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16861101" @default.
• W2000061026 hasPublicationYear "2006" @default.
• W2000061026 type Work @default.
• W2000061026 sameAs 2000061026 @default.
• W2000061026 citedByCount "21" @default.
• W2000061026 countsByYear W20000610262012 @default.
• W2000061026 countsByYear W20000610262013 @default.
• W2000061026 countsByYear W20000610262018 @default.
• W2000061026 countsByYear W20000610262019 @default.
• W2000061026 countsByYear W20000610262022 @default.
• W2000061026 countsByYear W20000610262023 @default.
• W2000061026 crossrefType "journal-article" @default.
• W2000061026 hasAuthorship W2000061026A5024768165 @default.
• W2000061026 hasAuthorship W2000061026A5047362217 @default.
• W2000061026 hasAuthorship W2000061026A5052145058 @default.
• W2000061026 hasAuthorship W2000061026A5069963123 @default.
• W2000061026 hasAuthorship W2000061026A5071835676 @default.
• W2000061026 hasAuthorship W2000061026A5077744833 @default.
• W2000061026 hasConcept C118552586 @default.
• W2000061026 hasConcept C126322002 @default.
• W2000061026 hasConcept C142724271 @default.
• W2000061026 hasConcept C168563851 @default.
• W2000061026 hasConcept C187212893 @default.
• W2000061026 hasConcept C204787440 @default.
• W2000061026 hasConcept C27081682 @default.
• W2000061026 hasConcept C2776174506 @default.
• W2000061026 hasConcept C2776412080 @default.
• W2000061026 hasConcept C2776809841 @default.
• W2000061026 hasConcept C2780057945 @default.
• W2000061026 hasConcept C2780733359 @default.
• W2000061026 hasConcept C2780820931 @default.
• W2000061026 hasConcept C2908647359 @default.
• W2000061026 hasConcept C558461103 @default.
• W2000061026 hasConcept C67761136 @default.
• W2000061026 hasConcept C70410870 @default.
• W2000061026 hasConcept C71924100 @default.
• W2000061026 hasConcept C99454951 @default.
• W2000061026 hasConceptScore W2000061026C118552586 @default.
• W2000061026 hasConceptScore W2000061026C126322002 @default.
• W2000061026 hasConceptScore W2000061026C142724271 @default.
• W2000061026 hasConceptScore W2000061026C168563851 @default.
• W2000061026 hasConceptScore W2000061026C187212893 @default.
• W2000061026 hasConceptScore W2000061026C204787440 @default.
• W2000061026 hasConceptScore W2000061026C27081682 @default.
• W2000061026 hasConceptScore W2000061026C2776174506 @default.
• W2000061026 hasConceptScore W2000061026C2776412080 @default.
• W2000061026 hasConceptScore W2000061026C2776809841 @default.
• W2000061026 hasConceptScore W2000061026C2780057945 @default.
• W2000061026 hasConceptScore W2000061026C2780733359 @default.
• W2000061026 hasConceptScore W2000061026C2780820931 @default.
• W2000061026 hasConceptScore W2000061026C2908647359 @default.
• W2000061026 hasConceptScore W2000061026C558461103 @default.
• W2000061026 hasConceptScore W2000061026C67761136 @default.
• W2000061026 hasConceptScore W2000061026C70410870 @default.
• W2000061026 hasConceptScore W2000061026C71924100 @default.
• W2000061026 hasConceptScore W2000061026C99454951 @default.
• W2000061026 hasIssue "5" @default.
• W2000061026 hasLocation W20000610261 @default.
• W2000061026 hasLocation W20000610262 @default.
• W2000061026 hasOpenAccess W2000061026 @default.
• W2000061026 hasPrimaryLocation W20000610261 @default.
• W2000061026 hasRelatedWork W1969601983 @default.
• W2000061026 hasRelatedWork W2000061026 @default.
• W2000061026 hasRelatedWork W2065544568 @default.
• W2000061026 hasRelatedWork W2097701869 @default.
• W2000061026 hasRelatedWork W2119707980 @default.
• W2000061026 hasRelatedWork W2166454988 @default.
• W2000061026 hasRelatedWork W2281626178 @default.
• W2000061026 hasRelatedWork W2987115618 @default.
• W2000061026 hasRelatedWork W4319293915 @default.
• W2000061026 hasRelatedWork W790984995 @default.

• next